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Sites of Failure in Breast Cancer Patients with Extra-
capsular Invasion of Axillary Lymph Node Metastases 
No Need for Axillary Irradiation?! 
Günther Gruber1, Samuel Menzi1, Andrea Forster1, Gilles Berclaz2, Hans-Jörg Altermatt3, 
Richard H. Greiner1  
Background and Purpose: Extracapsular spread (ECS) is frequent, but the specific sites of relapse are seldom given in the lit-
erature. In this study it was evaluated, if ECS might be an indicator for axillary irradiation. 
Patients and Methods: After a retrospective review of pathology reports, the information about ECS was available in 254 lymph 
node-positive patients: ECS was absent in 34% (ECS-negative; n = 87) and present in 66% (ECS-positive; n = 167). All patients 
were irradiated locally, 78 patients got periclavicular and 74 axillary irradiation (median total dose: 50.4 Gy). 240/254 patients 
(94.5%) received systemic treatment/s. Mean follow-up was 46 months. 
Results: The regional relapse rate was 4.6% without ECS versus 9.6% with ECS. The 5-year axillary relapse-free survival was 100% 
in ECS-negative and 90% in ECS-positive patients (p = 0.01), whereas corresponding values for periclavicular relapse-free survival 
(with ECS: 91% ± 4%; without ECS: 94% ± 3%; p = 0.77) and local relapse-free survival (with ECS: 86% ± 4%; without ECS: 91% ± 
3%; p = 0.69) were not significantly different. χ2-tests revealed a high correlation of ECS with T-stage, number of positive lymph 
nodes and progesterone receptor status, comparisons with estrogen receptor, grade, or age were not significant. In multivariate 
analysis number of positive lymph nodes was solely significant for regional failure. Dividing the patients into those with one to 
three and those with four or more positive lymph nodes, ECS lost its significance for axillary failure. 
Conclusion: ECS was accompanied by an enhanced axillary failure rate in univariate analysis, which was no longer true after 
adjusting for the number of positive lymph nodes. 
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Rückfallmuster beim nodal positiven Mammakarzinom mit extrakapsulärer Ausdehnung. Kein Grund zur Axilla-
bestrahlung?! 
Hintergrund und Ziel: Extrakapsuläres Tumorwachstum (ECS) befallener axillärer Lymphknoten ist häufig und wird als Parameter 
einer erhöhten lokoregionären Rezidivrate angesehen. In der Literatur sind erstaunlich wenig Informationen bezüglich spezifi-
scher Lokalisationen eventueller Rezidive erhältlich. In dieser Studie sollte das ECS als eventuelle Indikator für eine Bestrahlung 
der Axilla evaluiert werden. 
Patienten und Methodik: Es wurden nur jene 254 nodal positiven Patientinnen ausgewertet, bei denen gemäß histologischem 
Bericht zum Vorliegen oder Fehlen von ECS klar Stellung genommen wurde: In 66% (ECS-positiv; n = 167) wurde ECS beschrieben, 
und in 34% fehlte es (ECS-negativ; n = 87). Alle Patientinnen wurden lokal bestrahlt, 78 davon auch periklavikulär und 74 axillär 
(mediane Gesamtdosis: je 50,4 Gy). 240/254 Patientinnen (94,5%) erhielten Systemtherapie/n. Die mittlere Nachbeobachtungs-
zeit betrug 46 Monate.
Ergebnisse: Die regionäre Rezidivrate betrug 4,6% ohne ECS versus 9,6% mit ECS. Das axilläre rezidivfreie 5-Jahres-Überleben 
war 100% bei ECS-negativen und 90% bei ECS-positiven Patientinnen (p = 0,01). Die korrespondierenden Werte für das periklavi-
kuläre rezidivfreie Überleben (mit ECS: 91% ± 4%; ohne ECS: 94% ± 3%; p = 0,77) und das lokalrezidivfreie Überleben (mit ECS: 
86% ± 4%; ohne ECS: 91% ± 3%; p = 0,69) waren nicht signifikant unterschiedlich. ECS (ja/nein) korrelierte signifikant mit dem 
T-Stadium, der Anzahl positiver Lymphknoten und dem Progesteronrezeptorstatus, dagegen nicht mit dem Östrogenrezeptor, dem 
Tumorgrad oder dem Alter. Multivariat war die Anzahl positiver Lymphknoten der einzige signifikante Parameter für das regionale 
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Introduction 
The presence of extracapsular spread (ECS) of axillary lymph 
node metastasis/metastases is often correlated with locoregion-
al failure [11]. Therefore, ECS is considered to be an indication 
for axillary radiotherapy in some textbooks [2, 21]. In fact, only 
few publications evaluated the prognostic role of ECS and even 
less reports deal with the different sites of relapse. A lot of con-
troversy exists about the necessity of regional irradiation espe-
cially to the axilla. It is unclear, if the risk of axillary recurrence 
justifies the enhanced risk of toxicity (e.g., lymphedema, im-
paired shoulder movement) caused by irradiation to this site. 
We aimed to compare the failure pattern in node-positive 
breast cancer patients related to the presence or absence of 
ECS with a special emphasis on axillary recurrence. 
Patients and Methods 
As the information of ECS is not always prospectively recorded 
in the pathology report, only lymph node-positive patients with 
a clear definition of the presence or absence of ECS were eli-
gible for this retrospective review. ECS was defined as any 
breech of the capsule of one or more metastatic lymph node/s.
Between 08/1988 and 12/2001, 254 node-positive breast 
cancer patients with a median age of 56 years (range: 26–87 
years) could be identified, 167 (66%) of them with ECS. All 
patients had segmental mastectomy with axillary node dissec-
tion (level I, II, ± III; n = 144) or modified radical mastectomy 
(n = 110). The median number of resected lymph nodes was 
17 (range: one to 68), of which a median of three (range: one 
to 49) were positive. In eleven patients (4%) the total num-
ber of lymph nodes could not exactly be defined because of 
conglomeration. According to the pathologic report “many 
lymph nodes were metastatic”, and these patients were in-
cluded in the subgroup with more than three positive lymph 
nodes for further analyses. No patient had evidence of distant 
metastasis after staging which included routine chest X-rays, 
blood tests, liver ultrasounds, bone scans, and, in several cases, 
computed tomographies of the thorax. 
240 out of 254 patients (94.5%) received systemic adju-
vant treatment/s: 160 hormonal treatment (154 tamoxifen; six 
toremifen), and 204 chemotherapy. The chemotherapeutic 
regimens were anthracycline-based in 120 patients (in com-
bination with taxanes in seven patients and with CMF in 61 
patients). 84 patients received chemotherapy with CMF only. 
Radiotherapy was applied in every patient. The clinical 
target volume (CTV) enclosed the chest wall or the breast 
without defined inclusion of the lymph node regions in 
176 patients with a median total dose of 50.4 Gy (range: 
32.6–66.6 Gy). In 78 patients the periclavicular region and in 
74 of these patients the axillary region were irradiated with 
a median dose of 50.4 Gy. A boost with a median dose of 
10 Gy was applied in 93 patients. No special attempt was un-
dertaken to include the lymph nodes of the mammaria in-
terna region. 
Table 1 summarizes the clinicopathologic characteristics 
stratified according to the presence or absence of ECS. 
Statistical Methods 
Cross tabulations between ECS-positive and ECS-negative 
patients in regard to clinicopathologic parameters were cal-
Tumorrezidiv. Nach der Stratifikation der Patientinnen in solche mit ein bis drei und solche mit vier oder mehr positiven Lymph-
knoten ließ sich keine Signifikanz von ECS für die axilläre Rezidivhäufigkeit mehr finden.
Schlussfolgerung: In der univariaten Analyse war das Vorliegen von ECS mit einer erhöhten axillären Rezidivhäufigkeit vergesell-
schaftet. Dies konnte nach Aufteilung in ein bis drei und vier oder mehr positive Lymphknoten nicht mehr beobachtet werden. 
Schlüsselwörter:  Extranodal · Rezidivmuster · Axilläres Versagen · Multivariat 
Table 1. Distribution of clinicopathologic parameters in patients with 
or without extracapsular spread (ECS). 
Tabelle 1. Verteilung klinischer und pathologischer Parameter bei Pa-
tientinnen mit oder ohne extrakapsuläres Wachstum (ECS). 
All patients With ECS Without ECS p-valuea
n = 254 n = 167  n = 87  (two-sided)
 (66%) (34%)
 n (%) n (%)
Age ≤ 50 years   49 (29) 36 (41)    0.068
Age > 50 years 118 (71) 51 (59)
Grade 1     2   (1)   2   (2)    0.52
Grade 2   93 (56) 52 (60)
Grade 3   65 (39) 28 (32)
Grade x     7   (4)   5   (6)
Estrogen receptor negative   53 (32) 22 (25)     0.31
Estrogen receptor positive 114 (68) 65 (75) 
Progesterone receptor negative   65 (39) 22 (25)    0.036
Progesterone receptor positive 102 (61) 65 (75)
T-stage 1 + 2 112 (67) 75 (86)    0.001
T-stage 3 + 4   55 (33) 12 (14)
Positive nodes
• 1–3   61 (37) 70 (80) < 0.001
• ≥ 4 106 (63) 17 (20)
Radiotherapy
• Local only   83 (50) 82 (94) < 0.001
• Locoregional   84 (50)   5   (6)
Systemic therapy
• Nob     9   (6)   5   (6)    0.061
• Hormonal therapy   23 (14) 13 (15)
• Chemotherapy   44 (26) 36 (41)
• Hormonal therapy/chemotherapy   91 (54) 33 (38)
adone by Fisher’s exact test or Pearson’s χ2-test
bdue to patient’s refusal
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culated using Fisher’s exact test or Pearson’s χ2-test. Recur-
rence was divided into local, axillary, periclavicular (= supra-
clavicular + infraclavicular), and distant. The Kaplan-Meier 
method was used for the estimation of survival times, and 
the log-rank test for univariate analyses of various param-
eters as to local relapse-free survival (LRFS), axillary re-
lapse-free survival (ARFS), periclavicular relapse-free sur-
vival (PRFS), and distant metastasis-free survival (DMFS). 
Regional failure (= axillary + periclavicular failure) was of 
special interest, and all factors were also evaluated in mul-
tivariate analysis for this endpoint using the Cox regression 
proportional hazard model. A p-value < 0.05 was considered 
statistically significant. 
Results 
ECS was present in 66% of patients. Patients with ECS had 
more T3/T4 tumors (p = 0.001), a higher number of posi-
tive lymph nodes (p < 0.001) and more often progesterone 
receptor-negative tumors (p = 0.036). There was also a high 
imbalance regarding the treatment field selection of post-
operative radiotherapy, as in general, patients without ECS 
were irradiated only locally (p < 0.001). No significant dif-
ference could be observed in relation to 
age, grade, estrogen receptor or the use 
of systemic therapies. Details of the dif-
ferent patient characteristics are given 
in Table 1. 
Sites of First Failure (Table 2) 
After a mean follow-up of 46 months, 
26 patients relapsed locally. Local fail-
ures were equally distributed in both 
groups (with ECS: 17/167, 10.2%; 
without ECS: 9/87, 10.3%). Regional 
failures occurred in 20 patients (7.9%): 
axillary in eight, supraclavicular in 
seven, axillary + supraclavicular in three, 
infraclavicular in two patients. There 
was no failure in the mammary chain 
region. 
The regional relapse rate was 4.6% 
in patients without ECS versus 9.6% in 
patients with ECS. No axillary failure 
could be observed in the absence of 
ECS. Distant failures were also less fre-
quent in patients without ECS, 15% and 
33.5%, respectively. 
Table 2. Pattern of failure in patients with or without extracapsular spread (ECS). A: axillary; I: infraclavicular; S: supraclavicular. 
Tabelle 2. Rezidivmuster von Patientinnen mit oder ohne extrakapsuläres Wachstum (ECS). A: axillär; I: infraklavikulär; S: supraklavikulär. 
Site of first failure All patients Without ECS With ECS
 n = 254 n = 87 n = 167
 n (%) n (%) n (%)
Local only   6   (2.4)   4   (4.6)   2   (1.2)
Regional only   1   (0.4) (1× I)   1   (1.1) (1× I)   0
Distant only 45 (17.7)   8   (9.2) 37 (22.2)
Local + regional   0   0   0
Local + distant   5   (2.0)   2   (2.3)   3   (1.8)
Regional + distant   4   (1.6) (2× A; 2× S)   0   4   (2.4) (2× A; 2× S)
Local + regional + distant 15   (5.9) (3× A + S; 5× S; 1× I; 6× A)   3   (3.4) (3× S) 12   (7.2) (3× A + S; 2× S; 1× I; 6× A)
All local 26 (10.2)   9 (10.3) 17 (10.2)
All regional 20   (7.9)   4   (4.6) 16   (9.6) 
All distant 69 (27.2) 13 (15.0) 56 (33.5)
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Figure 1. Axillary relapse-free survival in 254 node-positive patients according to extracapsular 
spread. 
Abbildung 1. Axilläres rezidivfreies Überleben bei 254 nodal positiven Patientinnen in Abhän-
gigkeit vom extrakapsulären Wachstum. 
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Survival Analyses 
The 5-year regional relapse-free survival (RRFS) was 94% 
± 3% for patients without and 84% ± 4% for patients with 
ECS (p = 0.07). Dividing regional failures to specific sites, 
the ARFS was significantly decreased 
in patients with ECS. The 5-year ARFS 
for these patients was 90% ± 3% com-
pared to 100% in patients without ECS 
(p = 0.01; Figure 1). There was no signifi-
cant difference in the 5-year PRFS (with 
ECS: 91% ± 4%; without ECS: 94% ± 
3%; p = 0.77; Figure 2) and the 5-year 
LFRS (with ECS: 86% ± 4%; without 
ECS: 91% ± 3%; p = 0.69; Figure 3). 
Multivariate analysis for regional 
failure using Cox regression analysis 
was subsequently performed (Table 3). 
The only significant factor was the num-
ber of positive lymph nodes (p = 0.007), 
whereas other parameters like ECS or 
radiation treatment volume were not 
significant. 
The next step to evaluate the role of 
ECS for axillary and periclavicular fail-
ure was to divide the patients into two 
subgroups according to the number of 
positive lymph nodes. There were 131 
patients with one to three, and 123 pa-
tients with four or more positive nodes. 
We could not detect a significant differ-
ence in patients with or without ECS in 
both subgroups; however; the p-value for 
axillary failure was 0.07 in patients with 
one to three positive nodes (Figure 4). 
Discussion 
The likelihood of ECS rises with the 
number of positive lymph nodes [24]. 
In our series ECS was found in 47% of 
patients with one to three nodes, but in 
86% of patients with four or more nodes. 
This positive correlation was highly sig-
nificant and goes in line with a previous 
examination [7] and other data in the 
literature [1, 3, 9, 13]. This is probably 
the main reason why an independent 
prognostic role of ECS is difficult to de-
termine. 
First reports which found a corre-
lation of ECS with decreased survival 
were published nearly 30 years ago [5, 
13] and have been confirmed by almost 
every study afterwards [1, 3, 10, 12, 14, 18, 
20]. Leonard et al. [12] showed that ECS 
and number of positive lymph nodes were both independent 
factors for decreased survival. Pierce et al. [18] reported on a 
three times higher risk of death for patients with ECS after 
adjusting for the number of positive nodes (p = 0.06). In a se-
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Figure 2. Periclavicular relapse-free survival in 254 node-positive patients according to extra-
capsular spread.
Abbildung 2. Periklavikuläres rezidivfreies Überleben bei 254 nodal positiven Patientinnen in 
Abhängigkeit vom extrakapsulären Wachstum.
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Figure 3. Local relapse-free survival in 254 node-positive patients according to extracapsular 
spread. 
Abbildung 3. Lokales rezidivfreies Überleben bei 254 nodal positiven Patientinnen in Abhän-
gigkeit vom extrakapsulären Wachstum. 
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ries with 483 node-positive patients of whom 219 presented 
ECS, Kahlert et al. [10] found that this pathologic feature was 
significant in multivariate analysis with a relative risk of 1.6. 
This figure is similar to the risk ratio of 1.77 (p = 0.1) and 1.7 
(p = 0.1) in two other studies [3, 14]. The interpretation, how-
ever, is difficult, as they all differ in patient selection and the 
use of both, radiotherapy and systemic treatments. The same 
is true for the current study, but all of our patients got irradia-
tion and nearly 95% also systemic therapy. 
If we assume that all node-positive breast cancer patients 
should receive postoperative radiotherapy after breast-con-
serving surgery [15, 26] and mastectomy [16, 17, 19, 27], the 
question remains about the necessity of regional irradiation, 
especially if ECS is present. There is a lack of information 
about the specific sites of locoregional failure in the litera-
ture. Our primary interest was the influence of ECS on axil-
lary failure.
In general, axillary failure rates are low [22]: in patients 
without axillary irradiation 1/122 (0.8%) [9], 1/43 (2.3%) [1], 
1/20 (5%) [12], 1/27 (3.7%) [18], and 0/6 (0%) [25] patients 
relapsed in the axilla. As parts of it are often encompassed by 
tangential chest/breast irradiation, series without any irradia-
tion are more appropriate for failure rate definition, but even 
then axillary relapses are low: 0/62 (0%) [3], 2/28 (7.1%) [1], 
6/82 (7%) [4], 0/43 (0%) [14], and 1/85 (1.2%) [6]. We experi-
enced eleven failures out of 167 ECS-positive patients (6.6%). 
According to Kaplan-Meier plots, the actuarial axillary failure 
rate at 5 years was 10% versus 0% in the control group. There 
was no axillary failure even with four or more positive lymph 
nodes in the absence of ECS, and according to this result axil-
lary irradiation can be omitted. 
Patients with ECS experienced more axillary failures at 
least in univariate analysis, and despite the fact that patients 
with ECS got more often regional irradiation. To diminish this 
potential bias, a Cox regression analysis 
including the extent of irradiation (local 
vs. locoregional) was performed. The 
number of positive lymph nodes was 
the only significant factor for regional 
failure. Dividing the patients into those 
with one to three and those with four or 
more positive lymph nodes, ECS lost its 
prognostic value. Regional recurrence is 
uncommon in patients with one to three 
positive lymph nodes and ECS [23]. The 
number of positive lymph nodes might 
be much more important than ECS in 
the consideration of axillary irradiation.
Interestingly, all but one regional 
relapses were accompanied by distant 
failure. With few exceptions regional 
recurrences are likely to be an indicator 
of a systemic disease. It is questionable, 
if regional irradiation can alter the out-
come in these patients. 
Due to the retrospective design and 
a relatively small patient cohort firm 
conclusions cannot be made, but based 
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Figure 4. Axillary relapse-free survival in 131 patients with one to three positive lymph nodes 
according to extracapsular spread. 
Abbildung 4. Axilläres rezidivfreies Überleben bei 131 Patientinnen mit ein bis drei positiven 
Lymphknoten in Abhängigkeit vom extrakapsulären Wachstum. 
Table 3. Multivariate analysis (Cox regression proportional hazard) for 
“regional failure”. CI: confidence interval; CT: chemotherapy; HT: hor-
monal therapy; RR: relative risk. 
Tabelle 3. Multivariate Analyse („Cox regression proportional hazard“) 
für „regionales Rezidiv“. CI: Konfidenzintervall; CT: Chemotherapie; HT: 
Hormontherapie; RR: relatives Risiko. 
Parameter p-value RR (95% CI)
Number of positive nodes 0.007 0.25 (0.09–0.68)
(1–3; ≥ 4)
Age 0.27 0.60 (0.24–1.48)
(> 50 years; ≤ 50 years)
Estrogen receptor 0.14 0.52 (0.21–1.24)
(positive; negative)
Progesterone receptor 0.82 0.89 (0.32–2.45)
(positive; negative)
T-stage 0.30 0.55 (0.18–1.69)
(T1/2; T3/4)
Grade 0.89 1.05 (0.50–2.24)
(G1; G2; G3; Gx)
Extracapsular spread 0.62 1.38 (0.39–4.34)
(yes; no)
Systemic therapy 0.43 0.81 (0.48–1.37)
(no; CT; HT; CT + HT)
Radiotherapy 0.15 2.14 (0.77–5.96)
(local; locoregional)
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on our findings and data from the literature we do not support 
axillary irradiation regardless if ECS is present or not. The in-
clusion of the axillary apex and subclavian area is appropriate 
for selected node-positive cases, particularly those with four 
or more positive nodes [8]. Ongoing and future studies have 
to demonstrate which patients might benefit from additional 
regional radiation treatment. 
Despite the frequency of ECS in node-positive breast 
cancer data about the prognostic role of ECS are rare, and 
the current evaluation represents one of the largest in the lit-
erature. We could not find any significant differences in lo-
cal or periclavicular relapse rates between ECS-positive and 
ECS-negative patients. In the absence of ECS there was no 
axillary relapse, and irradiation of the axilla can be omitted in-
dependent of the number of positive lymph nodes. In patients 
with ECS axillary failures are more common, but probably on 
the basis of a more aggressive disease. If adjuvant irradiation 
of the axilla or other lymph node regions can alter the progno-
sis is still an open field for investigation. 
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